Amoxicillin | Amoxi-clavulanate | Cephalosporins | Macrolides | Total | |
Pharyngotonsillitis | |||||
1 year | 257 (31.4%) | 409 (50.1%) | 108 (13.2%) | 42 (5.3%) | 816 |
2–5 years | 696 (24.6%) | 1.648 (58.2%) | 354 (12.5%) | 131 (4.7%) | 2829 |
6–9 years | 272 (21.1%) | 781 (60.4%) | 156 (12.2%) | 83 (6.3%) | 1292 |
10–13 years | 74 (15.1%) | 305 (62.2%) | 48 (9.8%) | 63 (12.9%) | 490 |
Overall | 1299 (23.9%) | 3143 (57.9%) | 666 (12.3%) | 319 (5.9%) | 5427 |
Otitis media | |||||
1 year | 215 (32.4%) | 359 (53.9%) | 79 (11.9%) | 12 (1.8%) | 665 |
2–5 years | 452 (21.4%) | 1315 (62.2%) | 310 (14.7%) | 36 (1.7%) | 2113 |
6–9 years | 111 (16.0%) | 473 (68.0%) | 100 (14.4%) | 11 (1.6%) | 695 |
10–13 years | 22 (9.0%) | 189 (77.5%) | 25 (10.2%) | 8 (3.3%) | 244 |
Overall | 800 (21.5%) | 2336 (62.8%) | 514 (13.8%) | 67 (1.9%) | 3717 |
URTIs not otherwise specified | |||||
1 year | 344 (29.6%) | 604 (52.0%) | 134 (11.5%) | 78 (6.6%) | 1160 |
2–5 years | 411 (20.4%) | 1060 (52.4%) | 305 (15.1%) | 246 (12.1%) | 2022 |
6–9 years | 52 (10.7%) | 285 (58.5%) | 65 (13.4%) | 86 (17.4%) | 488 |
10–13 years | 20 (9.8%) | 106 (52.2%) | 16 (7.9%) | 61 (30.1%) | 203 |
Overall | 827 (21.3%) | 2055 (53.1%) | 520 (13.5%) | 471 (12.1%) | 3873 |
URTI, upper respiratory tract infection.